iRETINA
Financiado
Development of a multilayered and bioprinted iPSC-derived retinal model with use in preclinical and toxicological testing
Age-related macular degeneration (AMD) encompass the most prevalent cause of vision-loss in elderly people in developed countries. One of the main hurdles restraining the development of efficient treatments against AMD is the inab...
Age-related macular degeneration (AMD) encompass the most prevalent cause of vision-loss in elderly people in developed countries. One of the main hurdles restraining the development of efficient treatments against AMD is the inability of current animal, 2D-cellular and organoid-based models to completely recapitulate the pathophysiology of this disease. The goal of the iRETINA project is to bioprint an in-vitro human retinal model using isolated endothelial and retinal cells derived from iPSCs. The result will be a functional and vascularized iPSC-derived tissue resembling the native stratified retina that could serve as a preclinical and toxicological model for drug development and for the study of complex phenomena such as allogenic immune response. In order to achieve this goal, the iRETINA project will focus at three different levels: 1) implementing state-of-the-art genome editing tools for the development of retinal cell differentiation and enrichment strategies from healthy and AMD-patient iPSC; 2) developing new methodologies for bioprinting endothelial and retinal cells aiming to preserve cell viability, synaptic connectivity and structural integrity; 3) proof of concept testing to evaluate the usefulness of the artificial retina as a bona fide in vitro retinal model. The nature of this project is strongly multidisciplinary and involves the collaboration of basic researchers with experts in the fields of ophthalmology, immunology and biomaterial sciences. The results of this proposal have the potential to represent a true technological and scientific breakthrough that will result in better organ and disease modeling, and reduced laboratory animal use, eventually minimizing the burden and complexity of preclinical trials required for the development of novel pharmacological and cell replacement therapies against AMD.
ver más
Duración del proyecto: 43 meses
Fecha Inicio: 2022-06-30
Fecha Fin: 2026-02-28
Fecha Fin: 2026-02-28
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-06-30
HORIZON EUROPE
No se conoce la línea exacta de financiación, pero conocemos el organismo encargado de la revisión del proyecto.
Líder del proyecto
FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD
No se ha especificado una descripción o un objeto social para esta compañía.
N.D. |
Participante
N.D. |
Participante